CSBio CSBio

X
[{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma, Biosolution to market CartiLife in South Korea","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mundipharma"}]

Find Novel Musculoskeletal Drugs in Clinical Development in GERMANY

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.

            Lead Product(s): Chondrocytes

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Biosolution

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY